Serum Adiponectin, a Novel Biomarker Correlates with Skin Thickness in Systemic Sclerosis

The aim was to evaluate the longitudinal association between basal serum adiponectin and repeated measurements of skin thickness during 12 months of follow-up in systemic sclerosis (SSc) patients. We enrolled SSc patients with disease duration > 2 years in a prospective observational study. Skin thickness was measured at baseline and after 12 months of follow-up with modified Rodnan skin score (mRSS). Baseline serum adiponectin was determined using a commercial ELISA kit. We enrolled 66 female SSc patients (median age 54 years, IQR 42-62 years). The median disease duration was 12 (IQR 8-16) years and median baseline serum adiponectin was 9.8 (IQR 5.6-15.6) mcg/mL. The median mRSS was 10 (IQR 6-18) at baseline and 12 (IQR 7-18) at follow-up. A significant correlation was observed between baseline serum adiponectin and disease duration (r = 0.264, p < 0.05), age (r = 0.515, p < 0.0001), baseline mRSS (r = -0.303, p < 0.05), and mRSS at follow-up (r = -0.322, p < 0.001). In multiple regression analysis, only mRSS at follow-up showed an inverse correlation with baseline serum adiponectin (beta = -0.132, p < 0.01). The reduction in serum adiponectin levels is correlated with skin thickness.

Automated summary

This study aimed to evaluate the longitudinal association between basal serum adiponectin and skin thickness in systemic sclerosis (SSc) patients. The results showed a correlation between decreased serum adiponectin levels and increased skin thickness.